RxDoctor Payments Data

Jeremy Katzmann, MD

Family Medicine · Lakeland, FLNPI 1730151770

Payments from drug & device makers

$384in general payments, 2019–2025

Across 23 payments — averaging $16.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$194
  • GSK$49
  • Pfizer$35
  • AbbVie$31
  • Hydrofera LLC$24
  • Smith+Nephew$20
  • plus $31 from 2 others

What the payments were for

  • Food & beverage$35793%
  • Education$277%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Abbott12$194
GSK3$49
Pfizer2$35
AbbVie2$31
Hydrofera LLC1$24
Smith+Nephew1$20
Boehringer Ingelheim1$20
AstraZeneca1$12

How this compares

$384 in reported general payments places this provider in the 45th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$180,432
Medicare patients
573
Services billed
2,347

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban268$292,902
JardianceEmpagliflozin155$191,630
OzempicSemaglutide92$89,018
CopaxoneGlatiramer Acetate12$83,998
Repatha SureclickEvolocumab77$74,161
MounjaroTirzepatide56$62,840
JanuviaSitagliptin Phosphate41$54,571
XareltoRivaroxaban41$51,403
TrulicityDulaglutide19$25,565
FarxigaDapagliflozin Propanediol15$19,702
Repatha SyringeEvolocumab11$17,013
Trelegy ElliptaFluticasone/Umeclidin/Vilanter18$16,750
ShingrixVaricella-Zoster Ge/As01b/Pf72$15,660
MyrbetriqMirabegron19$12,021
VascepaIcosapent Ethyl13$10,672

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$35$292,902268 claims
Boehringer IngelheimJardiance, Combivent Respimat$20$198,572169 claims
GSKTrelegy Ellipta, Shingrix, Arexvy, Breo Ellipta$49$42,807120 claims
AstraZenecaFarxiga, Symbicort$12$26,53441 claims
AbbVieLinzess, Synthroid$31$14,666134 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Lakeland

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →